Compare Merck & Co., Inc. (MRK) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X Robo Global Robotics & Automation ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Global X Robo Global Robotics & Automation ETF trades at $81.26 (market cap $2.06B). The key difference: Merck & Co., Inc. is far larger — about 170.5× Global X Robo Global Robotics & Automation ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Global X Robo Global Robotics & Automation ETF for 36 Days on average.
| MRK | ROBO | |
|---|---|---|
Market Cap | $351.28B | $2.06B |
Volume | 7,969,665 | 148,111 |
Sector | Health | Sector/Thematic |
52-Week High | $156.43 | $90.34 |
52-Week Low | $82.49 | $63.04 |
Typical Hold Time | 98 Days | 36 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
ROBO trades at $81.26, down 0.68% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong institutional interest in robotics and AI themes, with recent news highlighting accelerating adoption across manufacturing, healthcare, and military applications. Financial ratios are unavailable in the current dataset.
The robotics sector offers long-term growth potential amid labor shortages and AI integration, though high RSI levels suggest near-term overbought conditions. Key risks include valuation concerns and sector competition, while analyst coverage remains favorable for diversified robotics exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
